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a b s t r a c t
Butyrylcholinesterase is a stoichiometric bioscavenger against poisoning by organophosphorus pesti-
cides and nerve agents. The low level of expression and extremely rapid clearance of monomeric re-
combinant human butyrylcholinesterase (rhBChE) from bloodstream (t½z2 min) limits its
pharmaceutical application. Recently (Ilyushin at al., PNAS, 2013) we described a long-acting poly-
sialylated recombinant butyrylcholinesterase (rhBChE-CAO), stable in the bloodstream, that protects
mice against 4.2 LD50 of VR. Here we report a set of modiﬁcations of the initial rhBChE expression vector
to improve stability of the enzyme in the bloodstream and increase its production in CHO cells by
introducing in the expression cassette: (i) the sequence of the natural human PRAD-peptide in frame
with rhBChE gene via “self-processing” viral F2A peptide under control of an hEF/HTLV promoter, and (ii)
previously predicted in silico MAR 1-68 and MAR X-29 sequences. This provides fully tetrameric rhBChE
(4rhBChE) at 70 mg/l, that displays improved pharmacokinetics (t½ ¼ 32 ± 1.2 h, MRT ¼ 43 ± 2 h). 3D
Fluorescent visualization and distribution of 125I-labeled enzyme reveals similar low level 4rhBChE and
rhBChE-CAO accumulation in muscle, fat, and brain. Administered 4rhBChE was mainly catabolized in
the liver and breakdown products were excreted in kidney. Injection of 1.2 LD50 and 1.1 LD50 of paraoxon
to BALB/c and knockout BChE/ mice pre-treated with 4rhBChE (50 mg/kg) resulted in 100% and 78%
survival, respectively, without perturbation of long-term behavior. In contrast, 100% mortality of non-
pre-treated mice was observed. The high expression level of 4rhBChE in CHO cells permits consider-
ation of this new expression system for manufacturing BChE as a biopharmaceutical.
© 2015 Published by Elsevier B.V.
1. Introduction
Chemical and nuclear weapons gave many dramatic war epi-
sodes in the 20th century. The Geneva Protocol, signed in 1925,
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